Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
CCT244747
128
CHF
CHF 128.00
In stock
SYN-1216-M0011 mgCHF 128.00
SYN-1216-M0055 mgCHF 270.00
SYN-1216-M01010 mgCHF 412.00
SYN-1216-M05050 mgINQ
| Product Details | |
|---|---|
| Synonyms | (R)-3-((1-(Dimethylamino)propan-2-yl)oxy)-5-((4-methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)pyrazine-2-carbonitrile |
| Product Type | Chemical |
| Properties | |
| Formula | C20H24N8O2 |
| MW | 408.5 |
| CAS | 1404095-34-6 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: CHK1 | Kinase Group: CAMK | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | IENLGMOXAQMNEH-CYBMUJFWSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
CCT244747 is a novel, potent, highly selective, orally active, ATP competitive CHK1 inhibitor. CCT244747 can inhibit cellular CHK1 activity with an IC50 of 29-170nM. In multiple tumour cell models, this has the effect of significantly enhancing the cytotoxicity of several anticancer drugs (such as gemcitabine and irinotecan) and abrogating drug-induced S and G2 arrest.
Product References
- Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors: M. Lainchbury, et al.; J. Med. Chem. 55, 10229 (2012)
- CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs: M.I. Walton, et al.; Clin. Cancer Res. 18, 5650 (2012)
- The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment: I. Patties, et al.; J. Exp. Clin. Cancer Res. 38, 420 (2019)
Related Products
